Ryan S Hsi1, Phyllis L Yan2, Joseph J Crivelli3, David S Goldfarb4, Vahakn Shahinian2, John M Hollingsworth5. 1. Department of Urology, Vanderbilt University Medical Center, Nashville, TN. 2. Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI. 3. Department of Urology, University of Alabama at Birmingham School of Medicine, Birmingham, AL. 4. Nephrology Section, VA New York Harbor Healthcare System, Division of Nephrology, New York University Langone Medical Center, Ney York, NY. 5. Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI. Electronic address: kinks@med.umich.edu.
Abstract
OBJECTIVE: To compare the frequency of stone-related events among subgroups of high-risk patients with and without 24-hour urine testing before preventive pharmacological therapy (PPT) prescription. While recent studies show, on average, no benefit to a selective approach to PPT for urinary stone disease (USD), there could be heterogeneity in treatment effect across patient subgroups. MATERIALS AND METHODS: Using medical claims data from working-age adults and their dependents with USD (2008-2019), we identified those with a prescription fill for a PPT agent (thiazide diuretic, alkali therapy, or allopurinol). We then stratified patients into subgroups based on the presence of a concomitant condition or other factors that raised their stone recurrence risk. Finally, we fit multivariable regression models to measure the association between stone-related events (emergency department visit, hospitalization, and surgery) and 24-hour urine testing before PPT prescription by high-risk subgroup. RESULTS: Overall, 8369 adults with USD had a concomitant condition that raised their recurrence risk. Thirty-three percent (n = 2722) of these patients were prescribed PPT after 24-hour urine testing (median follow-up, 590 days), and 67% (n = 5647) received PPT empirically (median follow-up, 533 days). Compared to patients treated empirically, those with a history of recurrent USD had a significantly lower hazard of a subsequent stone-related event if they received selective PPT (hazard ratio, 0.83; 95% confidence interval, 0.71-0.96). No significant associations were noted for selective PPT in the other high-risk subgroups. CONCLUSION: Patients with a history of recurrent USD benefit from PPT when guided by findings from 24-hour urine testing.
OBJECTIVE: To compare the frequency of stone-related events among subgroups of high-risk patients with and without 24-hour urine testing before preventive pharmacological therapy (PPT) prescription. While recent studies show, on average, no benefit to a selective approach to PPT for urinary stone disease (USD), there could be heterogeneity in treatment effect across patient subgroups. MATERIALS AND METHODS: Using medical claims data from working-age adults and their dependents with USD (2008-2019), we identified those with a prescription fill for a PPT agent (thiazide diuretic, alkali therapy, or allopurinol). We then stratified patients into subgroups based on the presence of a concomitant condition or other factors that raised their stone recurrence risk. Finally, we fit multivariable regression models to measure the association between stone-related events (emergency department visit, hospitalization, and surgery) and 24-hour urine testing before PPT prescription by high-risk subgroup. RESULTS: Overall, 8369 adults with USD had a concomitant condition that raised their recurrence risk. Thirty-three percent (n = 2722) of these patients were prescribed PPT after 24-hour urine testing (median follow-up, 590 days), and 67% (n = 5647) received PPT empirically (median follow-up, 533 days). Compared to patients treated empirically, those with a history of recurrent USD had a significantly lower hazard of a subsequent stone-related event if they received selective PPT (hazard ratio, 0.83; 95% confidence interval, 0.71-0.96). No significant associations were noted for selective PPT in the other high-risk subgroups. CONCLUSION: Patients with a history of recurrent USD benefit from PPT when guided by findings from 24-hour urine testing.
Authors: Jaclyn C Milose; Samuel R Kaufman; Brent K Hollenbeck; J Stuart Wolf; John M Hollingsworth Journal: J Urol Date: 2013-09-07 Impact factor: 7.450
Authors: Casey A Dauw; Yooni Yi; Maggie J Bierlein; Phyllis Yan; Abdulrahman F Alruwaily; Khurshid R Ghani; J Stuart Wolf; Brent K Hollenbeck; John M Hollingsworth Journal: J Urol Date: 2015-10-17 Impact factor: 7.450
Authors: Casey A Dauw; Samuel R Kaufman; Brent K Hollenbeck; William W Roberts; Gary J Faerber; J Stuart Wolf; John M Hollingsworth Journal: J Urol Date: 2013-09-20 Impact factor: 7.450
Authors: John M Hollingsworth; Edward C Norton; Samuel R Kaufman; R Matt Smith; J Stuart Wolf; Brent K Hollenbeck Journal: J Urol Date: 2013-03-19 Impact factor: 7.450
Authors: Shen Song; I-Chun Thomas; Calyani Ganesan; Ericka M Sohlberg; Glenn M Chertow; Joseph C Liao; Simon Conti; Christopher S Elliott; Alan C Pao; John T Leppert Journal: Clin J Am Soc Nephrol Date: 2019-11-11 Impact factor: 10.614
Authors: Giovanni Gambaro; Emanuele Croppi; Fredric Coe; James Lingeman; Orson Moe; Elen Worcester; Noor Buchholz; David Bushinsky; Gary C Curhan; Pietro Manuel Ferraro; Daniel Fuster; David S Goldfarb; Ita Pfeferman Heilberg; Bernard Hess; John Lieske; Martino Marangella; Dawn Milliner; Glen M Preminger; Jose' Manuel Reis Santos; Khashayar Sakhaee; Kemal Sarica; Roswitha Siener; Pasquale Strazzullo; James C Williams Journal: J Nephrol Date: 2016-07-25 Impact factor: 3.902
Authors: Ryan S Hsi; Phyllis L Yan; Joseph J Crivelli; David S Goldfarb; Vahakn Shahinian; John M Hollingsworth Journal: Urology Date: 2022-05-08 Impact factor: 2.633